WhiteLab Genomics Establishes US Presence by Securing Spot at Bayer Co.Lab and Ginkgo Bioworks’ Technology Network

Bayer’s Co.Lab in Cambridge is specifically designed to support startups with access to Bayer’s enterprise-wide cell and gene therapy expertise in addition to state-of-the art laboratory and office space. Situated in Kendall Square, hailed as « the most innovative mile on the planet, » startups that are part of Bayer’s Co.Lab can take advantage of being close to the discovery, development and commercial expertise at the Bayer Research Innovation Center (BRIC), as well as BlueRock (a CGT Bayer affiliate company), Beam Therapeutics and LabCentral 238, all housed within the same building. Co.Lab residents also benefit from its proximity to leading academia, medical schools, teaching hospitals, and trial centers. WhiteLab Genomics stands as one of nine companies chosen to join Bayer Co.Lab in Cambridge within its first year of operations.

“Joining the Bayer Co.Lab in Cambridge is a pivotal next step towards our US expansion. Leveraging Bayer’s rich expertise, we are confident this environment is ripe for transformative opportunities in healthcare, offering invaluable insights into the forefront of gene and cell therapy innovations. We are honored that WhiteLab has been selected for this incredible opportunity.” said David Del Bourgo, CEO and Co-Founder of WhiteLab Genomics.

Complementing its presence in key innovation hubs worldwide, Bayer’s global network Co.Lab incubators exemplify Bayer’s dedication to driving transformative progression in the life sciences.